RxDoctor Payments Data

Patrick Dominguez, MD

Dermatology · Orlando, FLNPI 1184891830

Payments from drug & device makers

$10,745in general payments, 2019–2025

Across 474 payments — averaging $22.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Lilly USA, LLC$960
  • Johnson & Johnson$913
  • Novartis$886
  • Sanofi$835
  • Regeneron Healthcare Solutions, Inc.$620
  • plus $5K from 23 others

What the payments were for

  • Food & beverage$10,30796%
  • Education$4384%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,745 in reported general payments places this provider in the 75th percentile of 1,147 dermatology providers in Florida.

See all dermatology providers in Florida

Medicare billing

Part B allowed, 2024
$25,455
Medicare patients
112
Services billed
354

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa22$464,005
Cosentyx Unoready PenSecukinumab17$229,382
Cosentyx Sensoready (2 Pens)Secukinumab20$167,944
OtezlaApremilast21$97,542
SotyktuDeucravacitinib15$97,358
Clobetasol Propionate175$8,459
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc93$5,401
Fluorouracil26$2,851
Mometasone Furoate124$2,555
Tretinoin34$2,291
Metronidazole32$1,954
Triamcinolone Acetonide146$1,618
Fluocinonide30$1,312
Ketoconazole70$1,257
Betamethasone Dipropionate29$1,106

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$487$97,54221 claims
E.r. Squibb & Sons, L.L.C.Sotyktu$400$97,35815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,147 dermatology providers in Florida.

Other dermatology in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →